Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer
Oncology · 2023
DOI: 10.1159/000533303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2023. Verfasst von Norio Akuta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Telomerase, Liver Neoplasms, Biomarkers, Tumor, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Personalized medicine and molecular therapies with the diagnosis of somatic genetic alterations are expected to be developed for liver cancer. Nevertheless, it is unknown whether a mutation in the telomere reverse transcriptase promoter (TERT C228T) in serum cfDNA might be useful for making prognostic predictions after surgical resection for primary liver cancer.
Methods
This cohort study retrospectively investigated 111 patients who had undergone surgical resection of liver cancer for the first time. We investigated the differences between clinicopathological features and prognosis according to classification of three tumor markers, including AFP, PIVKAII, and TERT C228T.
Results
Multivariate analysis identified etiology (fatty liver disease vs. HBV odds ratio [OR] 6.853) and fibrosis stage (2–4, OR: 0.137) as determinants of TERT C228T-positive liver cancer with normal levels of AFP and PIVKAII (TERT single positive liver cancer). TERT single positive (Yes, OR: 0.301), fibrosis (FIB)-4 index (≥3.25, OR: 2.038), Child-Pugh classification (B, OR: 4.975), and number of tumors (≥2, OR: 4.098) were identified as determinants of the recurrence of liver cancer. TERT single positive (Yes, OR: 3.311), FIB-4 index (≥3.25, OR: 0.433), and number of tumors (≥2, OR: 0.262) were identified as determinants of disease-free survival.
Conclusions
Our results highlight the impact of classification of prognostic tumor markers. TERT single positive is one predictor of favorable prognosis after surgical resection for liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
- Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan.
Zitieren
APA
Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Saitoh, S., Kobayashi, M., Arase, Y., Ikeda, K., Suzuki, Y., Kumada, H., & Suzuki, F. (2023). Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer. Oncology. https://doi.org/10.1159/000533303
Vancouver
Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, et al. Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer. Oncology. 2023. doi:10.1159/000533303
BibTeX
@article{Akuta2023,
author = {Akuta, Norio and Kawamura, Yusuke and Fujiyama, Shunichiro and Sezaki, Hitomi and Hosaka, Tetsuya and Saitoh, Satoshi and Kobayashi, Mariko and Arase, Yasuji and Ikeda, Kenji and Suzuki, Yoshiyuki and Kumada, Hiromitsu and Suzuki, Fumitaka},
title = {Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer},
journal = {Oncology},
year = {2023},
doi = {10.1159/000533303}
}
EUVIMED